Besides, we examined the expression levels of mesenchymal marker (N-cadherin) in clinical specimens, and explored it could be a potential indicator to predict the therapeutic outcome to CCRT treatment in ESCC patients. This evidence concerns the gene CDH2 and esophageal squamous cell carcinoma.